evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

2,805 questions · 2,912 findings · 307 reviews · Headline outcomes only

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 706 · 24.2%GRADE not reported 133 · 4.6%Very low 786 · 27%Low 696 · 23.9%Moderate 474 · 16.3%High 117 · 4%

Condiments/seasonings fortified with iron plus other micronutrients vs condiments/seasonings fortified with other micronutrients except iron

Haemoglobin (g/dL) · population aged 2 years and above (Andersson 2008 ‐ 5‐18 years, Asibey‐Berko 2007 ~ 3 years, Chen Ke 2008 ‐ 2‐6 years, Haas 2014 ‐ women…
1 finding from 1 review

Methylphenidate vs placebo or no intervention

Proportion of participants with one or more serious adverse events · Children and adolescents with ADHD

It is very uncertain whether methylphenidate changes proportion of participants with one or more serious adverse events compared with placebo or no intervention (very low certainty).

1 finding from 1 review

Methylphenidate vs placebo or no intervention

Adverse events considered non‐serious (penicillin versus doxycycline) · Children and adolescents with ADHD

It is very uncertain whether methylphenidate changes proportion of participants with one or more adverse events… compared with placebo or no intervention (very low certainty).

1 finding from 1 review

Methylphenidate vs placebo or no intervention

General behaviour: all parallel‐group trials and first‐period cross‐over trials General behaviour rating scales (Teacher‐rated) · Children and adolescents with ADHD

It is very uncertain whether methylphenidate changes general behaviour: all parallel‐group trials and first‐period… compared with placebo or no intervention (very low certainty).

1 finding from 1 review

Perampanel add‐on vs placebo

50% or greater reduction in seizure frequency · people (aged 12 years and over) with drug‐resistant focal epilepsy

Perampanel add‐on leads to higher ≥ 50% reduction in seizure frequency compared with placebo (high certainty).

1 finding from 1 review

Perampanel add‐on vs placebo

Withdrawals due to adverse events · people (aged 12 years and over) with drug‐resistant focal epilepsy

Perampanel add‐on may leads to higher treatment withdrawal due to adverse effects compared with placebo (low certainty).

1 finding from 1 review

Perampanel add‐on vs placebo

Proportion of participants who experienced ≥ 1 adverse effect · people (aged 12 years and over) with drug‐resistant focal epilepsy

Perampanel add‐on leads to higher proportion of participants who experienced ≥ 1 adverse effect compared with placebo (high certainty).

1 finding from 1 review

Perampanel add‐on vs placebo

Proportion of participants who experienced ataxia · people (aged 12 years and over) with drug‐resistant focal epilepsy

Perampanel add‐on may leads to higher proportion of participants who experienced ataxia compared with placebo (low certainty).

1 finding from 1 review

Summary of findings ‐ triple therapy: elexacaftor‐tezacaftor‐ivacaftor vs control (ivacaftor alone or tezacaftor plus ivacaftor)

Survival · adults and children aged 12 years and over with cystic fibrosis and either F508del/gating variant or F508del/residual function genotype
1 finding from 1 review

Summary of findings ‐ triple therapy: elexacaftor‐tezacaftor‐ivacaftor vs control (ivacaftor alone or tezacaftor plus ivacaftor)

Quality of life: total score · adults and children aged 12 years and over with cystic fibrosis and either F508del/gating variant or F508del/residual function genotype

The review found no eligible studies for this question.

1 finding from 1 review

Summary of findings ‐ triple therapy: elexacaftor‐tezacaftor‐ivacaftor vs control (ivacaftor alone or tezacaftor plus ivacaftor)

Quality of life: CFQ‐R respiratory domain: absolute change from baseline · adults and children aged 12 years and over with cystic fibrosis and either F508del/gating variant or F508del/residual function genotype

The review found no eligible studies for this question.

1 finding from 1 review

Summary of findings ‐ triple therapy: elexacaftor‐tezacaftor‐ivacaftor vs control (ivacaftor alone or tezacaftor plus ivacaftor)

FEV1 % predicted: relative change from baseline · adults and children aged 12 years and over with cystic fibrosis and either F508del/gating variant or F508del/residual function genotype

The review found no eligible studies for this question.

1 finding from 1 review

Summary of findings ‐ triple therapy: elexacaftor‐tezacaftor‐ivacaftor vs control (ivacaftor alone or tezacaftor plus ivacaftor)

FEV1 % predicted: absolute change from baseline · adults and children aged 12 years and over with cystic fibrosis and either F508del/gating variant or F508del/residual function genotype
1 finding from 1 review

Summary of findings ‐ triple therapy: elexacaftor‐tezacaftor‐ivacaftor vs control (ivacaftor alone or tezacaftor plus ivacaftor)

Adverse events ‐ treatment emergent · adults and children aged 12 years and over with cystic fibrosis and either F508del/gating variant or F508del/residual function genotype

Summary of findings ‐ triple therapy: elexacaftor‐tezacaftor‐ivacaftor showed no clear difference in adverse events: number of participants with treatment‐emergent… compared with control (ivacaftor alone or tezacaftor plus ivacaftor) (moderate certainty).

1 finding from 1 review

Summary of findings ‐ triple therapy: elexacaftor‐tezacaftor‐ivacaftor vs control (ivacaftor alone or tezacaftor plus ivacaftor)

Time to first pulmonary exacerbation · adults and children aged 12 years and over with cystic fibrosis and either F508del/gating variant or F508del/residual function genotype

The review found no eligible studies for this question.

1 finding from 1 review